Virtual opening event at Isobionics new distillation plant at site in Geleen, Netherlands
Geleen, Netherlands, February 11, 2021 – Toine Janssen, CEO of Isobionics® formally opened the new Isobionics distillation plant at Brightlands Chemelot Campus in Geleen, Netherlands. Steffen Götz, Head of BASF's Aroma Ingredients business, Jurgen Hoekstra, Managing Director BASF Nederland, and Bert Kip, CEO of Brightlands Chemelot Campus, joined the event virtually.
The Isobionics approach to producing natural fragrance and flavor ingredients is unique around the world. The company´s proprietary technology is based on fermentation, a traditional technique well known from processes such as brewing beer and baking bread. In this method, a substance is converted into a target product with the help of microorganisms such as bacteria or fungi. This process is based on renewable raw materials. Distillation is the last production step, yielding natural ingredients.
“With our new distillation plant, we can expand our business even faster and serve the needs of our customers. We have many new ingredients in development, some of them will be already launched this year,“ says Toine Janssen, CEO of Isobionics.
“The new distillation plant is another example how we connect the innovation power and scale-up capabilities of Isobionics and BASF – for one purpose: to best serve the needs of our customers,” says Steffen Götz, Head of BASF's Aroma Ingredients business.
“Thanks to the support from the Province of Limburg and the excellent facilities available at Brightlands Chemelot, we can now expand our distillation capacity. Isobionics' new fermentation-based products highlight the innovative strength of the ecosystem in the south of the Netherlands,” says Jurgen Hoekstra, Managing Director BASF Nederland.
The latest innovation: Isobionics® Santalol
Isobionics recently launched Isobionics Santalol. The proprietary manufacturing process makes the product unique. It is produced on a biotechnological basis from renewable raw materials: The starting material for the fermentation process is corn starch obtained from corn grown in Europe. The product is 100% free of the endangered sandalwood tree, which is on the Red List of the International Union for Conservation of Nature (IUCN). Isobionics Santalol is a close alternative to the original sandalwood oil, bringing warmth and volume to any fragrance creation while conserving natural resources. In addition, it offers consistent high quality and is independent of weather and harvesting conditions. This ensures stable product availability.
Isobionics is a leading innovator in fermentation, located in Geleen, Netherlands. The company develops and produces a wide range of ingredients for the F&F market with a focus on citrus oil components such as Valencene and Nootkatone. In 2019, Isobionics was acquired by BASF and became part of BASF’s Aroma Ingredients business.
About BASF’s Nutrition & Health division
BASF Nutrition & Health provides a comprehensive product and service range for human and animal nutrition, pharmaceutical, bioenergy and flavor & fragrance industries. With our science-driven portfolio, we address customers in globally growing markets to meet the demands of an expanding world population. Together with our customers, we play an active role in enhancing the nutrition, health and wellbeing of consumers all over the world. Our products fulfill the highest safety, regulatory and sustainability standards. BASF Nutrition & Health operates sites in Europe, North America, South America and in Asia-Pacific. For more information, go to www.basf.com.
At BASF, we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. More than 117,000 employees in the BASF Group work on contributing to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio is organized into six segments: Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care and Agricultural Solutions. BASF generated sales of €59 billion in 2019. BASF shares are traded on the stock exchange in Frankfurt (BAS) and as American Depositary Receipts (BASFY) in the U.S. Further information at www.basf.com.